Stryker Corporation
Stryker Reports Strong First Quarter 2024 Results
Summary
Stryker Corporation announced its first quarter 2024 operating results on April 30, 2024, reporting a 9.7% increase in net sales to $5.2 billion and a 33.1% increase in net earnings to $788 million. The company achieved organic net sales growth of 10.0% and an adjusted operating income margin of 21.9%. Stryker's CEO expressed confidence in the company's ability to drive strong earnings growth in 2024, with full-year organic net sales growth expected to be in the range of 8.5% to 9.5%. The press release also detailed segment performance, with MedSurg and Neurotechnology showing 11.5% net sales growth and Orthopaedics and Spine at 7.5%.
Profitelligence Alerts
Get alerts for SYK
Be first to know when Stryker Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Stryker Corporation
Stryker Corporation is a prominent player in the medical technology industry, known for its innovative solutions across healthcare sectors such as orthopedics, medical and surgical, and neurotechnology and spine. The company's purpose is to enhance patient care through its wide array of products, including surgical equipment and advanced medical devices. Stryker plays a critical role in the healthcare market by providing essential tools and technologies that assist in improving surgical precision and patient recovery processes. With a continuous focus on research and development, Stryker Corporation remains at the forefront of medical advancements, directly impacting hospitals, surgical centers, and healthcare providers globally. The company's extensive distribution network and partnerships with medical professionals ensure that its technologies contribute to improving health outcomes across diverse geographical regions.
Official SEC Documents
Advertisement